AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck & Co. and Sanofi would consider participating in a revised pilot program, COA says. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
